Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins

Microbes and Infection

Volumn 15, Issue 4, 2013, Pages 280-290

  Chutiwitoonchai, Nopporn ^a   Hiyoshi, Masateru ^a   Hiyoshi Yoshidomi, Yuka ^a   Hashimoto, Michihiro ^a   Tokunaga, Kenzo ^b   Suzu, Shinya ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Antiviral activity; APOBEC3G; HIV 1; IFITM; IFN; Tetherin

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; COMPLEMENTARY DNA; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; IFITM PROTEIN; IFITM3 PROTEIN; NEF PROTEIN; TETHERIN; UNCLASSIFIED DRUG; VIF PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CODON; CONTROLLED STUDY; DOWN REGULATION; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PALMITOYLATION; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; VIRUS IMMUNITY;

ANTIGENS, DIFFERENTIATION; CELL LINE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV-1; HUMANS; MEMBRANE PROTEINS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA-BINDING PROTEINS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORTHOMYXOVIRIDAE;

EID: 84876097576     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.12.003     Document Type: Article

References (41)

1. Liu S.Y., Sanchez D.J., Cheng G. New developments in the induction and antiviral effectors of type I interferon. Curr. Opin. Immunol. 2011, 23:57-64.
2. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008, 8:559-568.
3. Friedman R.L., Manly S.P., McMahon M., Kerr I.M., Stark G.R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984, 38:745-755.
4. Tanaka S.S., Yamaguchi Y.L., Tsoi B., Lickert H., Tam P.P. IFITM/Mil/fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Dev. Cell 2005, 9:745-756.
5. Brass A.L., Huang I.C., Benita Y., John S.P., Krishnan M.N., Feeley E.M., Ryan B.J., Weyer J.L., van der Weyden L., Fikrig E., Adams D.J., Xavier R.J., Farzan M., Elledge S.J. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 2009, 139:1243-1254.
6. Feeley E.M., Sims J.S., John S.P., Chin C.R., Pertel T., Chen L.M., Gaiha G.D., Ryan B.J., Donis R.O., Elledge S.J., Brass A.L. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog. 2011, 7:e1002337.
7. Yount J.S., Moltedo B., Yang Y.Y., Charron G., Moran T.M., López C.B., Hang H.C. Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 2010, 6:610-614.
8. Jiang D., Weidner J.M., Qing M., Pan X.B., Guo H., Xu C., Zhang X., Birk A., Chang J., Shi P.Y., Block T.M., Guo J.T. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J. Virol. 2010, 84:8332-8341.
9. Huang I.C., Bailey C.C., Weyer J.L., Radoshitzky S.R., Becker M.M., Chiang J.J., Brass A.L., Ahmed A.A., Chi X., Dong L., Longobardi L.E., Boltz D., Kuhn J.H., Elledge S.J., Bavari S., Denison M.R., Choe H., Farzan M. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 2011, 7:e1001258.
10. Weidner J.M., Jiang D., Pan X.B., Chang J., Block T.M., Guo J.T. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 2010, 84:12646-12657.
11. Raychoudhuri A., Shrivastava S., Steele R., Kim H., Ray R., Ray R.B. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J. Virol. 2011, 85:12881-12889.
12. Lu J., Pan Q., Rong L., Liu S.L., Liang C. The IFITM proteins inhibit HIV-1 infection. J. Virol. 2011, 85:2126-2137.
13. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., Rice C.M. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
14. Neil S.J., Sandrin V., Sundquist W.I., Bieniasz P.D. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein. Cell Host Microbe 2007, 2:193-203.
15. Neil S.J., Zang T., Bieniasz P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451:425-430.
16. Van Damme N., Goff D., Katsura C., Jorgenson R.L., Mitchell R., Johnson M.C., Stephens E.B., Guatelli J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3:245-252.
17. Dubé M., Roy B.B., Guiot-Guillain P., Mercier J., Binette J., Leung G., Cohen E.A. Suppression of tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J. Virol. 2009, 83:4574-4590.
18. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Kräusslich H.G., Fackler O.T., Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5:285-297.
19. Miyagi E., Andrew A.J., Kao S., Strebel K. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:2868-2873.
20. Chen K., Huang J., Zhang C., Huang S., Nunnari G., Wang F.X., Tong X., Gao L., Nikisher K., Zhang H. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 2006, 80:7645-7657.
21. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2003, 418:646-650.
22. Mariani R., Chen D., Schröfelbauer B., Navarro F., König R., Bollman B., Münk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31.
23. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 2003, 12:591-601.
24. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 2003, 9:1398-1403.
25. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302:1056-1060.
26. Mangeat B., Turelli P., Liao S., Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 2004, 279:14481-14483.
27. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 2004, 279:7792-7798.
28. Iwabu Y., Fujita H., Kinomoto M., Kaneko K., Ishizaka Y., Tanaka Y., Sata T., Tokunaga K. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284:35060-35072.
29. Nomaguchi M., Doi N., Fujiwara S., Fujita M., Adachi A. Site-directed mutagenesis of HIV-1 vpu gene demonstrates two clusters of replication-defective mutants with distinct ability to down-modulate cell surface CD4 and tetherin. Front. Microbiol. 2010, 1:116.
30. Chutiwitoonchai N., Hiyoshi M., Mwimanzi P., Ueno T., Adachi A., Ode H., Sato H., Fackler O.T., Okada S., Suzu S. The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement. PLoS ONE 2011, 6:e27696.
31. Nguyen K.L., Llano M., Akari H., Miyagi E., Poeschla E.M., Strebel K., Bour S. Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004, 319:163-175.
32. Hiyoshi M., Suzu S., Yoshidomi Y., Hassan R., Harada H., Sakashita N., Akari H., Motoyoshi K., Okada S. Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor. Blood 2008, 111:243-250.
33. Hassan R., Suzu S., Hiyoshi M., Takahashi-Makise N., Ueno T., Agatsuma T., Akari H., Komano J., Takebe Y., Motoyoshi K., Okada S. Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms. J. Cell. Physiol. 2009, 221:458-468.
34. Chihara T., Suzu S., Hassan R., Chutiwitoonchai N., Hiyoshi M., Motoyoshi K., Kimura F., Okada S. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010, 17:1917-1927.
35. Suzu S., Harada H., Matsumoto T., Okada S. HIV-1 Nef interferes with M-CSF receptor signaling through Hck activation and inhibits M-CSF bioactivities. Blood 2005, 105:3230-3237.
36. Garcia J.V., Miller A.D. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991, 350:508-511.
37. Suhasini M., Reddy T.R. Cellular proteins and HIV-1 Rev function. Curr. HIV Res. 2009, 7:91-100.
38. Cao Y., Liu X., De Clercq E. Cessation of HIV-1 transcription by inhibiting regulatory protein Rev-mediated RNA transport. Curr. HIV Res. 2009, 7:101-108.
39. Clerzius G., Gélinas J.F., Gatignol A. Multiple levels of PKR inhibition during HIV-1 replication. Rev. Med. Virol. 2011, 21:42-53.
40. Jammi N.V., Whitby L.R., Beal P.A. Small molecule inhibitors of the RNA-dependent protein kinase. Biochem. Biophys. Res. Commun. 2003, 308:50-57.
41. Couturier J., Paccalin M., Morel M., Terro F., Milin S., Pontcharraud R., Fauconneau B., Page G. Prevention of the β-amyloid peptide-induced inflammatory process by inhibition of double-stranded RNA-dependent protein kinase in primary murine mixed co-cultures. J. Neuroinflammation 2011, 8:72.